Clinical Safety and Tolerability of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Botulinum Neurotoxin Subtype A2, in Comparison with Subtype A1 Toxins
All the botulinum type A neurotoxins available for clinical use are of the A1 subtype. We developed a subtype A2 low-molecular-weight (150 kD (kilo Dalton)) neurotoxin (A2NTX) with less spread and faster entry into the motor nerve terminal than A1 in vitro and in vivo. Preliminary clinical studies s...
Guardado en:
Autores principales: | Toshiaki Takeuchi, Tsuyoshi Okuno, Ai Miyashiro, Tomoko Kohda, Ryosuke Miyamoto, Yuishin Izumi, Shunji Kozaki, Ryuji Kaji |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9a9ff29f6a3843ac893cb75e843cbfad |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6
por: Molly S. Moritz, et al.
Publicado: (2018) -
The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes
por: Sabine Pellett, et al.
Publicado: (2018) -
Botulinum Neurotoxin-Producing Bacteria. Isn’t It Time that We Called a Species a Species?
por: Theresa Smith, et al.
Publicado: (2018) -
Recombinant botulinum neurotoxin serotype A1 in vivo characterization
por: Cindy Périer, et al.
Publicado: (2021) -
Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified <named-content content-type="genus-species">Clostridium botulinum</named-content> Strain
por: Sabine Pellett, et al.
Publicado: (2016)